Hormonal Approach for Postmenopausal Vulvovaginal Atrophy

Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve that significantly affects the genital tract. Although postmenopausal vulvovaginal atrophy primarily affects postmenopausal women, it is also seen in premenopausal women. The hypoestrogenic cond...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ana Paula Ferreira Costa, Ayane Cristine Alves Sarmento, Pedro Vieira-Baptista, José Eleutério, Ricardo Ney Cobucci, Ana Katherine Gonçalves
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	menopause vulvovaginal atrophy hormone therapy estrogen DHEA testosterone Reproduction QH471-489 Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b1cdcdff0ff94a3493ddce814ad69de0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b1cdcdff0ff94a3493ddce814ad69de0
record_format	dspace
spelling	oai:doaj.org-article:b1cdcdff0ff94a3493ddce814ad69de02021-12-01T14:11:57ZHormonal Approach for Postmenopausal Vulvovaginal Atrophy2673-315310.3389/frph.2021.783247https://doaj.org/article/b1cdcdff0ff94a3493ddce814ad69de02021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/frph.2021.783247/fullhttps://doaj.org/toc/2673-3153Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve that significantly affects the genital tract. Although postmenopausal vulvovaginal atrophy primarily affects postmenopausal women, it is also seen in premenopausal women. The hypoestrogenic condition results in hormonal and anatomical changes, with the main symptoms, are dryness, burning and genital irritation, decreased lubrication, urinary urgency, dysuria, and recurrent urinary tract infections. This review aims to update hormone therapy for urogenital atrophy, both local and systemic, and discusses the importance of understanding and the need for active treatment of this condition. The main therapeutic objective is the relief of symptoms, and hormonal therapy (HT) is still the most effective choice for treating clinical manifestations, despite the side effects of its use. HT should be used in an individualized way to the needs of the women and appropriate to the stage in which she is menopausal, perimenopausal, or after menopause.Ana Paula Ferreira CostaAyane Cristine Alves SarmentoPedro Vieira-BaptistaPedro Vieira-BaptistaJosé EleutérioRicardo Ney CobucciAna Katherine GonçalvesAna Katherine GonçalvesFrontiers Media S.A.articlemenopausevulvovaginal atrophyhormone therapyestrogenDHEAtestosteroneReproductionQH471-489Medicine (General)R5-920ENFrontiers in Reproductive Health, Vol 3 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	menopause vulvovaginal atrophy hormone therapy estrogen DHEA testosterone Reproduction QH471-489 Medicine (General) R5-920
spellingShingle	menopause vulvovaginal atrophy hormone therapy estrogen DHEA testosterone Reproduction QH471-489 Medicine (General) R5-920 Ana Paula Ferreira Costa Ayane Cristine Alves Sarmento Pedro Vieira-Baptista Pedro Vieira-Baptista José Eleutério Ricardo Ney Cobucci Ana Katherine Gonçalves Ana Katherine Gonçalves Hormonal Approach for Postmenopausal Vulvovaginal Atrophy
description	Menopause is a physiological and progressive phenomenon secondary to decreased ovarian follicular reserve that significantly affects the genital tract. Although postmenopausal vulvovaginal atrophy primarily affects postmenopausal women, it is also seen in premenopausal women. The hypoestrogenic condition results in hormonal and anatomical changes, with the main symptoms, are dryness, burning and genital irritation, decreased lubrication, urinary urgency, dysuria, and recurrent urinary tract infections. This review aims to update hormone therapy for urogenital atrophy, both local and systemic, and discusses the importance of understanding and the need for active treatment of this condition. The main therapeutic objective is the relief of symptoms, and hormonal therapy (HT) is still the most effective choice for treating clinical manifestations, despite the side effects of its use. HT should be used in an individualized way to the needs of the women and appropriate to the stage in which she is menopausal, perimenopausal, or after menopause.
format	article
author	Ana Paula Ferreira Costa Ayane Cristine Alves Sarmento Pedro Vieira-Baptista Pedro Vieira-Baptista José Eleutério Ricardo Ney Cobucci Ana Katherine Gonçalves Ana Katherine Gonçalves
author_facet	Ana Paula Ferreira Costa Ayane Cristine Alves Sarmento Pedro Vieira-Baptista Pedro Vieira-Baptista José Eleutério Ricardo Ney Cobucci Ana Katherine Gonçalves Ana Katherine Gonçalves
author_sort	Ana Paula Ferreira Costa
title	Hormonal Approach for Postmenopausal Vulvovaginal Atrophy
title_short	Hormonal Approach for Postmenopausal Vulvovaginal Atrophy
title_full	Hormonal Approach for Postmenopausal Vulvovaginal Atrophy
title_fullStr	Hormonal Approach for Postmenopausal Vulvovaginal Atrophy
title_full_unstemmed	Hormonal Approach for Postmenopausal Vulvovaginal Atrophy
title_sort	hormonal approach for postmenopausal vulvovaginal atrophy
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/b1cdcdff0ff94a3493ddce814ad69de0
work_keys_str_mv	AT anapaulaferreiracosta hormonalapproachforpostmenopausalvulvovaginalatrophy AT ayanecristinealvessarmento hormonalapproachforpostmenopausalvulvovaginalatrophy AT pedrovieirabaptista hormonalapproachforpostmenopausalvulvovaginalatrophy AT pedrovieirabaptista hormonalapproachforpostmenopausalvulvovaginalatrophy AT joseeleuterio hormonalapproachforpostmenopausalvulvovaginalatrophy AT ricardoneycobucci hormonalapproachforpostmenopausalvulvovaginalatrophy AT anakatherinegoncalves hormonalapproachforpostmenopausalvulvovaginalatrophy AT anakatherinegoncalves hormonalapproachforpostmenopausalvulvovaginalatrophy
_version_	1718405080654282752

Hormonal Approach for Postmenopausal Vulvovaginal Atrophy

Ejemplares similares